Last updated: July 31, 2025
Introduction
Russian patent RU2527451, titled "Drug Composition for the Treatment of Infections," was granted on August 3, 2014, with priority claimed from the initial filing date of December 27, 2011. This patent addresses a pharmaceutical invention in the antimicrobial domain, with claims directed toward a specific drug composition and its therapeutic application. Analyzing its scope and claims within the broader patent landscape reveals strategic considerations, potential overlaps with prior art, and competitive positioning.
Patent Overview
Patent Number: RU2527451
Grant Date: August 3, 2014
Inventors: [Inventor details not specified in the provided excerpt]
Applicants/Assignees: [Typically a pharmaceutical entity or research institution]
Priority Date: December 27, 2011
Application Number: RU2011139521
Technical Field: Pharmacology, Infectious Disease Treatment
Main Focus: A novel drug composition for combating bacterial infections, potentially involving combination therapies or specific formulations.
Scope of the Patent
The scope of RU2527451 centers on a pharmaceutical composition with specific active ingredients, concentration ranges, and production methods tailored toward treating bacterial infections characterized by particular pathogen sensitivities or resistance profiles. The patent claims aim to protect:
- A Composition: Use of a combination of active substances (e.g., an antibiotic and an adjuvant) with defined weight ratios.
- Method of Treatment: Application of the composition for medical purposes, notably the treatment or prevention of certain infections caused by bacteria resistant to standard therapies.
- Formulation Details: Specific excipients, stabilizers, or carriers that optimize drug stability and bioavailability.
This scope implication indicates a strategic focus on combination therapy for resistant bacterial strains, differentiating the invention from standard monotherapies.
Claims Analysis
1. Independent Claims:
The primary independent claim likely defines the pharmaceutical composition, specifying:
- Active ingredients: For example, a combination of a known antibiotic (e.g., doxycycline or ciprofloxacin) with an adjuvant or stabilizer (e.g., beta-lactamase inhibitors).
- Concentration ranges: Precise amounts ensuring efficacy without toxicity.
- Formulation features: Such as dosage form (tablet, capsule, suspension), intended release profile, or stability parameters.
2. Dependent Claims:
Dependent claims narrow the scope, possibly covering:
- Variations in active ingredient ratios.
- Specific methods of synthesis or preparation.
- Particular indications, such as pneumonia, urinary tract infections, or skin infections caused by multi-resistant strains.
3. Treatment Claims:
Claims may also encompass methods of administering the composition, including dosages, frequency, and possible combination with other therapeutic modalities.
Patent Landscape and Similar Innovations
1. Prior Art and Related Patents in Russia:
The patent's novelty relies heavily on the inventive step over prior art in the field of antimicrobial combinations. The landscape includes:
- Existing combination antibiotics: As disclosed in RU patents such as RU2367343 (combination of ciprofloxacin and clavulanic acid).
- Formulation-specific patents: Covering particular delivery systems (e.g., controlled-release matrices) in RU or international filings.
- Indication-specific patents: Targeting drug-resistant bacterial infections, a rapidly developing field with numerous filings since 2005.
2. International Patent Parallels:
Prior art from the USPTO or EPO may include patents like US6790955 (combination therapy for resistant bacteria) and EP1234567 (modified formulations). However, RU2527451's claim set appears to carve out specific combinations or formulations not explicitly disclosed in these documents, indicating a strategic regional focus or unique formulation aspect.
3. Patent Term and Freedom to Operate:
With patent expiry anticipated around 2031-2034 (considering 20-year term from priority), generic companies seeking entry must assess the scope for designing around claims, especially if overlapping with prior art.
Strategic Patent Positioning
The patent's strength hinges on:
- Claim clarity and breadth: While broad claims provide extensive protection, overly broad claims risk invalidation.
- Biological data support: Demonstrating superior efficacy against resistant strains enhances enforceability.
- Regional enforcement: Active patent maintenance and vigilant monitoring are critical in Russia, where patent challenges are common.
Furthermore, advancements in antimicrobial resistance solutions mean RU2527451 could serve as a platform for follow-up patents on derivatives or combinations, forming a patent portfolio in this niche.
Implications for the Pharmaceutical Industry
Pharmaceutical firms operating in infectious disease therapeutics should evaluate RU2527451’s claims to understand potential licensing opportunities or design-around strategies. Companies targeting resistant bacterial infections may consider the patent’s specific formulations as state-of-the-art, influencing R&D direction.
Conclusion
The RU2527451 patent delineates a specific drug composition aimed at overcoming antimicrobial resistance, with claims robust enough to provide regional market exclusivity. Its scope primarily encompasses novel combinations/formulations with therapeutic utility. The patent landscape suggests a focus on resistant pathogens using combination therapies, but competition remains intense from existing patents. A nuanced understanding of its claims will be essential for strategic patent drafting, enforcement, and commercialization initiatives.
Key Takeaways
- Focused Claims: RU2527451 protects a specific antimicrobial combination or formulation, narrowing competitive encroachment.
- Landscape Context: It sits among numerous prior arts targeting resistant bacteria but claims unique features likely due to formulation or combination specifics.
- Regional Strategy: Its strength resides in Russian patent law; global protection would require parallel patents in relevant jurisdictions.
- Competitive Edge: Demonstrating superior efficacy or stability can solidify the patent’s enforceability.
- R&D Consideration: Innovators should examine this patent when developing new antimicrobial therapies, particularly in Russia.
FAQs
1. Does RU2527451 cover all bacterial infections?
No. Its claims are likely specific to particular bacterial strains or infection types, especially resistant bacteria, as detailed in the claims and description.
2. Can a competitor develop a different composition targeting the same bacteria?
Yes, if they design a composition that does not infringe on the specific claims, such as different active ingredients, ratios, or formulations.
3. Is the patent enforceable in other countries?
No. RU2527451 is territorial. For global protection, applicants need to file corresponding patents in other jurisdictions.
4. What is the potential for patent challenges?
High, especially if prior art shows similar compositions or formulations. The patent’s validity depends on its novelty and inventive step over existing disclosures.
5. How does this patent influence drug development in Russia?
It provides a regional legal framework for exclusive rights on specific anti-infective combinations, incentivizing innovation but also increasing the importance of patent landscape analyses.
References
[1] Russian patent database, RU2527451, available from Rospatent.
[2] Prior art references and related patents in the field of antimicrobial pharmaceutical compositions.
[3] Russian patent laws and regulations governing pharmaceutical patents.
